Business Overview: Longduoduo Company Limited (OTC: LDDD)

---

Executive Summary

Longduoduo Company Limited is a Nevada holding company with no operations of its own; all of its business is conducted through seven subsidiaries in the Inner Mongolia region of China, where the company sells preventive-healthcare and wellness services targeting cardiovascular and cerebrovascular disease, myocardial and cerebral infarction, hemiplegia, and gastrointestinal disorders. The company does not provide medical treatment itself — it sells access to services delivered by licensed third-party providers.

Since June 2023, the overwhelming majority of Longduoduo's revenue (over 99.6% of gross revenue in the fiscal year ended June 30, 2026) has come from acting as a commissioned sales agent for health-maintenance services developed by a related party, Inner Mongolia Honghai Health Management Co., Ltd. ("Honghai"), under agreements running through June 2029. A smaller, declining "principal sales" business resells services purchased from third-party providers such as hospitals directly to consumers in Hohhot, Ordos, Baotou, and Ulanqab.

It matters as a case study in single-counterparty commercial dependency: Longduoduo is a real, revenue-generating operating business with 51 employees, but its economics are now almost entirely a function of one commission agreement with one related-party service developer, and its revenue has fallen sharply (down roughly 42% in fiscal 2025 and 57% in fiscal 2026) as that model has matured.

---

1. Core Business Model & How They Work

Longduoduo's seven PRC operating subsidiaries act primarily as sales agents, marketing and collecting payment for health-maintenance services that a related party designs and is contractually responsible for delivering.

  Honghai Health Management          Longduoduo PRC Subsidiaries
  (designs & is responsible   ➡️     (market & sell services as
   for service quality)               commissioned sales agents)
                                              │
                                              ▼
                                    End Customers in Inner
                                 Mongolia (Hohhot, Ordos, Baotou,
                                           Ulanqab)
                                              │
                                              ▼
                           Subsidiaries collect customer payment,
                         remit to Honghai net of agreed commission
                                              │
                                              ▼
                              Commission income = ~99.6% of
                                  gross revenue (FY2026)

  (Secondary, shrinking line: subsidiaries also buy services from
   third-party providers like hospitals and resell directly — "principal
   sales" — revenue down ~95% year-over-year)

Services sold include immunological ozonated autohemotherapy, meridian-regulating and consciousness-restoring iatrotechnics, double blood purification, gut-microbiota products and testing, and PRP treatment — all delivered by licensed third-party medical providers who bear the clinical liability.

---

2. Business Segments

Longduoduo does not report distinct business segments in its Item 1 disclosure; it is best understood as a single integrated wellness-services sales business operating two sales models (commissioned agency sales, now dominant, and a shrinking principal-sales resale business) through its PRC subsidiary network, rather than as formal reportable segments.

---

3. Key Offerings

---

4. Competitive Landscape

• Major public hospitals — compete for the same preventive-care customer base with broader clinical credibility and government backing.
• Private medical companies, including large national firms — better-capitalized competitors with stronger brand recognition and greater resources, per the company's own disclosure.
• Regional providers and local independent medical centers — compete on local relationships and price within Inner Mongolia's specific cities.
• Other health sales agencies — direct competitors in the same commissioned-sales-agent model Longduoduo uses.

Longduoduo positions itself on sales and marketing execution, an "innovative approach," and a flexible management structure, while acknowledging that larger competitors have superior resources and brand recognition.

---

5. Strategic Strengths & Risks

Strengths:

• Established regional distribution network across four Inner Mongolia cities (Hohhot, Ordos, Baotou, Ulanqab) with real paying customers and real revenue, unlike a pure shell.
• Flexible, low-overhead sales-agency model that avoids the capital intensity and liability of directly providing medical treatment.

Risks:

• Extreme single-counterparty concentration — over 99.6% of gross revenue depends on commission payments under agreements with one related party, Honghai; any dispute, renegotiation, or deterioration in that relationship would be existential for the business.
• Related-party dependency — Honghai is a related party, raising governance and conflict-of-interest concerns around commission terms.
• Severe revenue decline — gross revenue fell from roughly $7.39 million (FY2024) to $4.26 million (FY2025) to $1.82 million (FY2026), a cumulative drop of roughly 75% over two years.
• Geographic and regulatory concentration — all operations and all 51 employees are located in the PRC, exposing the company to Chinese regulatory, healthcare-policy, and currency risk with no geographic diversification.
• Swing to a net loss — the company moved from net income of $0.46 million (FY2025) to a net loss of $(0.58) million (FY2026) as the commission revenue base shrank.

---

6. Financial Overview

(Fiscal year ends June 30; figures per company financial filings.)

---

7. Summary Conclusion

Longduoduo is a real, revenue-generating micro-cap operating business — not a shell — but its business model has consolidated almost entirely around a single commission agreement with a related party, Honghai, which now accounts for essentially all of its revenue. That concentration delivers extremely high gross margins when volume is healthy, but it also means the company has effectively no revenue diversification and very little negotiating leverage of its own. With gross revenue down roughly three-quarters over two fiscal years and the company swinging to a net loss in FY2026, the central forward question is whether Longduoduo can either renegotiate better terms under the Honghai agreement, rebuild its shrinking principal-sales business, or find a genuinely independent revenue stream before the Honghai relationship — the entire business, in practice — deteriorates further.